The U.S. House Energy & Commerce Committee has raised concerns with the FDA regarding Chinese supplies of heparin, an anticoagulant used in heart surgery. It has called for alternative supplies due to fraud concerns, though the likely increase in trade tensions between the two countries – which the forthcoming section 301 review of Chinese IP practices will worsen – is another good reason. Panjiva data shows U.S. imports of heparin and related products fell to the lowest since at least 2009 in November after Chinese imports (39% of the total) fell 9% in the 12 months to November 30. At t...